Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells

Mycoses

Volumn 50, Issue 3, 2007, Pages 172-177

  Falkensammer, Barbara ^a   Pilz, Georg ^a   Bektić, Jasmin ^a   Imwidthaya, Pankorn ^a,b   Jöhrer, Karin ^c   Speth, Cornelia ^a   Lass Flörl, Cornelia ^a   Dierich, Manfred P ^a   Würzner, Reinhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MAHIDOL UNIVERSITY   (Thailand)

^c TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Adherence; Candida albicans; Endothelial cells; Human immunodeficiency virus; Protease inhibitors

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANIMAL CELL; ARTICLE; CANDIDA ALBICANS; CELL ADHESION; CELL LINE; CELL TYPE; COLONY FORMING UNIT; DRUG MECHANISM; ENDOTHELIUM CELL; FUNGAL STRAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN;

CANDIDA ALBICANS; CELL ADHESION; CELL LINE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HIV PROTEASE INHIBITORS; HUMANS; UMBILICAL VEINS;

CANDIDA; CANDIDA ALBICANS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34247610953     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01353.x     Document Type: Article

References (29)

1. Odds FC. (ed.) Candida and candidosis. London : Balliere Tindall 1988.
2. Fidel PL. Immunity to Candida. Oral Dis 2002 8 : 69 75.
3. Korting HC, Ollert M, Georgii A, Frosch M. In vitro susceptibility and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol 1998 26 : 2626 31.
4. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996 334 : 1674 5.
5. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998 351 : 228 30.
6. White TC, Agabian M. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type; and levels are determined by environmental factors. J Bacteriol 1995 177 : 5215 21.
7. Gruber A, Speth C, Lukasser-Vogl E et al. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999 41 : 227 34.
8. Gruber A, Berlit J, Speth C et al. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors. Immunobiology 1999 201 : 133 44.
9. Gruber A, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP, Würzner R. Candida albicans: attenuation of fungal virulence properties in vitro by an HIV-1 protease inhibitor. Immunobiology 1998 199 : 647.
10. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999 180 : 448 53.
11. Korting HC, Schaller M, Eder G, Hamm G, Böhme, U, Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors Saquinavir and Indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 1999 43 : 2038 42.
12. Monod M, Borg-von Zepelin M, Telenti A, Sanglard D. The inhibition of Candida albicans-secreted aspartic proteases by three different HIV protease inhibitors. Dermatology 1999 198 : 412 4.
13. Munro CA, Hube B. Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol 2002 10 : 173 7.
14. Hube B, Naglik J. Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001 147 : 1997 2005.
15. Borg-von Zepelin M, Meyer I, Thomssen R et al. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 1999 113 : 747 51.
16. Bektic J, Lell CP, Fuchs A et al. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunol Med Microbiol 2001 31 : 65 71.
17. Würzner R, Langgartner M, Spötl L et al. Temperature-dependent surface expression of the β2-integrin analogue of Candida albicans and its role in adhesion to the human endothelium. Exp Clin Immunogenet 1996 13 : 162 73.
18. Holland JA, Pritchard KA, Rogers NJ, Stemerman MB. Perturbation of cultured human endothelial cells by atherogenic levels of low density lipoprotein. Am J Pathol 1988 132 : 474 8.
19. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973 52 : 2745 56.
20. Calderone RA, Fonzi WA. Virulence factors of Candida albicans. Trends Microbiol 2001 9 : 327 35.
21. Hoegl L, Thomagreber E, Rocken M, Korting HC. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. Mycoses 1998 41 : 321 5.
22. Cauda R, Tacconelli E, Tumbarello M et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999 21 : 20 5.
23. Cassone A, Tacconelli E, De Bernardis F et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis 2002 185 : 188 95.
24. De Bernardis F, Sullivan PA, Cassone A. Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 2001 39 : 303 13.
25. Schaller M, Korting HC, Schafer W, Bastert J, Chen W, Hube B. Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis. Mol Microbiol 1999 34 : 169 80.
26. Sanglard D, Hube B, Monod M, Odds FC, Gow GA. A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence. Infect Immun 1997 65 : 3539 46.
27. Ibrahim AS, Filler SG, Sanglard D, Edwards JE Jr., Hube B. Secreted aspartyl proteinases and interactions of Candida albicans with human endothelial cells. Infect Immun 1998 66 : 3003 5.
28. Felk A, Kretschmar M, Albrecht A et al. Candida albicans hyphal formation and the expression of the Efg1-regulated proteinases Sap4 to Sap6 are required for the invasion of parenchymal organs. Infect Immun 2002 70 : 3689 700.
29. De Bernardis F, Tacconelli E, Mondello F et al. Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. FEMS Immunol Med Microbiol 2004 41 : 27 34.